-
Selumetinib, a selective MEK1/2 inhibitor, achieved objective responses in 15% of patients with recurrent low-grade serous ovarian cancer (LGSOC). The data are relevant as this uncommon tumor type is associated with general chemoresistance, frequent aberration in the MAPK pathway, and prolonged overall survival compared with its more common high-grade variant. Phase 3 trials are planned.
-
A review of incident cases of venous thrombosis in women using oral contraceptives (OCs) in a U.S. insurance database found that use of drospirenone-containing OCs containing 20 ìg of ethinyl estradiol (EE) was associated with a two-fold increase in risk compared to levonorgestrel pills. This risk was not increased with use of 30 ìg EE drospirenone pills.
-
Low levels of anti-Müllerian hormone in combination with an elevated day 2-3 follicle-stimulating hormone is associated with a high rate of aneuploid embryos.
-
The authors performed a two-part analysis of the contraceptive choice Project, a prospective cohort study in which women in the St. Louis, Missouri, region received a reversible contraceptive method of their choice for up to 3 years at no cost.
-
Cholesterol-reducing statin agents have been associated preclinically with cancer cell growth inhibition and metastases prevention.
-
Conventional wisdom in obstetrics implies that woen with previous uterine surgery outside the lower uterine segment — whether myomectomy or classical cesarean section — incrue an unacceptable risk for uterine rupture during pregnancy.
-
-
1998 was a landmark year for men’s sexuality. the FDA approved sildenafil (Viagra®), a medication that now has household name familiarity.
-
In this issue: Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions.
-
In this sample of 102 consecutive Dutch patients with heavy menstrual bleeding, the overall prevalence of an underlying bleeding disorder was 29%, with the most common being disorders of platelet function.